Legacy Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,283
Closed -$243K – 322
2026
Q2
$243K Buy
+1,283
New +$241K 0.02% 288
2019
Q3
– Sell
-580
Closed -$48K – 131
2019
Q2
$48K Buy
+580
New +$45.5K 0.03% 208
2017
Q4
– Sell
-159
Closed -$10K – 351
2017
Q3
$10K Buy
+159
New +$10K 0.01% 216

Other funds holding AZN

Legacy Advisors's AZN Position: Q3 2026 in Review

Legacy Advisors sold out of AstraZeneca (AZN) in Q3 2026, closing a stake of 1,283 shares — an estimated $243K sold.

Legacy Advisors first reported a position in AZN in Q3 2017 and held it in 3 quarters. The position peaked at $243K in Q2 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Legacy Advisors reported no remaining AstraZeneca position as of Q3 2026 after selling out during the quarter.
  • Legacy Advisors sold 1,283 AstraZeneca shares in Q3 2026, an estimated $243K.
  • Legacy Advisors first reported a position in AstraZeneca in Q3 2017 and held it in 3 quarters.
  • Legacy Advisors's AstraZeneca position peaked at $243K in Q2 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Legacy Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.